Toll Free: 1-888-928-9744

Vaginal Cancer - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 72 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Vaginal Cancer - Pipeline Review, H1 2016


Global Markets Direct's, 'Vaginal Cancer - Pipeline Review, H1 2016', provides an overview of the Vaginal Cancer pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Vaginal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vaginal Cancer and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


- The report provides a snapshot of the global therapeutic landscape of Vaginal Cancer
- The report reviews pipeline therapeutics for Vaginal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Vaginal Cancer therapeutics and enlists all their major and minor projects
- The report assesses Vaginal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Vaginal Cancer

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Vaginal Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Vaginal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Vaginal Cancer Overview 7 Therapeutics Development 8 Pipeline Products for Vaginal Cancer - Overview 8 Vaginal Cancer - Therapeutics under Development by Companies 9 Vaginal Cancer - Pipeline Products Glance 10 Clinical Stage Products 10 Vaginal Cancer - Products under Development by Companies 11 Vaginal Cancer - Companies Involved in Therapeutics Development 12 ISA Pharmaceuticals B.V. 12 Nanotherapeutics, Inc. 13 Ono Pharmaceutical Co., Ltd. 14 Oryx GmbH & Co. KG 15 PDS Biotechnology Corporation 16 Taiwan Liposome Company, Ltd. 17 Vaginal Cancer - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Target 19 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Drug Profiles 27 ISA-101 - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 LN-145 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 nivolumab - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 NTO-1151 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 PDS-0101A - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 TLC-388 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Vicoryx - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Vaginal Cancer - Recent Pipeline Updates 45 Vaginal Cancer - Dormant Projects 70 Appendix 71 Methodology 71 Coverage 71 Secondary Research 71 Primary Research 71 Expert Panel Validation 71 Contact Us 71 Disclaimer 72
List of Tables
Number of Products under Development for Vaginal Cancer, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 10 Products under Development by Companies, H1 2016 11 Vaginal Cancer - Pipeline by ISA Pharmaceuticals B.V., H1 2016 12 Vaginal Cancer - Pipeline by Nanotherapeutics, Inc., H1 2016 13 Vaginal Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 14 Vaginal Cancer - Pipeline by Oryx GmbH & Co. KG, H1 2016 15 Vaginal Cancer - Pipeline by PDS Biotechnology Corporation, H1 2016 16 Vaginal Cancer - Pipeline by Taiwan Liposome Company, Ltd., H1 2016 17 Assessment by Monotherapy Products, H1 2016 18 Number of Products by Stage and Target, H1 2016 20 Number of Products by Stage and Mechanism of Action, H1 2016 22 Number of Products by Stage and Route of Administration, H1 2016 24 Number of Products by Stage and Molecule Type, H1 2016 26 Vaginal Cancer Therapeutics - Recent Pipeline Updates, H1 2016 45 Vaginal Cancer - Dormant Projects, H1 2016 70

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.